Gsk (GLAXF) Total Debt (2009 - 2026)

Gsk's Total Debt history runs 18 years deep, the most recent figure standing at -$18.9 billion for Q1 2026.

• In Q1 2026, Total Debt rose 8.96% year-over-year to -$18.9 billion; the TTM figure through Mar 2026 stood at -$18.9 billion (up 8.96% YoY), while the FY2025 annual figure was -$15.4 billion, down 171.18% from the prior year.
• Total Debt was -$18.9 billion for Q1 2026 at Gsk, down from -$15.6 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $22.3 billion in Q4 2023 to a low of -$23.7 billion in Q2 2022.
• Historically, Total Debt has averaged -$11.9 billion across 5 years, with a median of -$19.2 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Debt soared 60.47% in 2022, then plunged 171.52% in 2025.
• A 5-year view of Total Debt shows it stood at $21.5 billion in 2022, then increased by 3.97% to $22.3 billion in 2023, then dropped by 2.65% to $21.8 billion in 2024, then slumped by 171.52% to -$15.6 billion in 2025, then declined by 21.42% to -$18.9 billion in 2026.
• The last three Total Debt figures came in at -$18.9 billion (Q1 2026), -$15.6 billion (Q4 2025), and -$20.1 billion (Q3 2025), per Business Quant data.